Y Mabs Therapeutics Inc Quick Ratio (YMAB) starting from the second quarter 2025 to second quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Y mabs Therapeutics inc   (NASDAQ: YMAB)

Y Mabs Therapeutics Inc 's Quick Ratio

YMAB's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2025, Quick Ratio fell to 2.71 below Y Mabs Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 264 other companies have achieved higher Quick Ratio than Y Mabs Therapeutics Inc in second quarter 2025. While Quick Ratio total ranking in the second quarter 2025 has deteriorated compared to the prior quarter from 608 to 1104.

Explain Quick Ratio?
How much Cash & cash equivalents YMAB´s has?
What are YMAB´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

YMAB Quick Ratio (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2
Y / Y Current Liabilities Change -47.22 % 7.68 % 23.26 % 15.95 % 79.38 %
Y / Y Cash & cash equivalent Change -19.94 % -20.38 % -14.5 % -21.31 % -11.49 %
Quick Ratio MRQ 2.71 3.18 2.84 2.69 1.79
YMAB's Total Ranking # 1104 # 608 # 547 # 879 # 738
Seq. Current Liabilities Change 21.04 % -20.01 % -6.3 % -41.82 % 146.92 %
Seq. Cash & cash equivalent Change 3.29 % -10.3 % -1.3 % -12.45 % 2.72 %



Quick Ratio second quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 265
Healthcare Sector # 460
Overall Market # 1104


Quick Ratio Statistics
High Average Low
17.53 7.48 1.79
(Sep 30 2018)   (Jun 30 2024)




Financial Statements
Y Mabs Therapeutics Inc 's Current Liabilities $ 23 Millions Visit YMAB's Balance sheet
Y Mabs Therapeutics Inc 's Cash & cash equivalent $ 62 Millions Visit YMAB's Balance sheet
Source of YMAB's Sales Visit YMAB's Sales by Geography


Cumulative Y Mabs Therapeutics Inc 's Quick Ratio

YMAB's Quick Ratio for the trailling 12 Months

YMAB Quick Ratio

 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth -10.99 % 34.44 % 20.7 % 5.33 % -7.55 %
Y / Y Cash & cash equivalent TTM Growth -19.07 % -16.84 % -16.44 % -19.46 % -20.47 %
Quick Ratio TTM 2.84 2.45 2.62 2.84 3.12
Total Ranking TTM # 3433 # 2355 # 3132 # 3014 # 3205
Seq. Current Liabilities TTM Growth -18.42 % 1.23 % 4.24 % 3.41 % 23.21 %
Seq. Cash & cash equivalent TTM Growth -5.67 % -5.34 % -3.8 % -5.79 % -3.07 %

Quick ratio ranking by company, industry and sector >> Back to YMAB Financial Strength Comparisons >> Go to Compare YMAB Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Y Mabs Therapeutics Inc 's average Cash & cash equivalent, this led to increase in in Y Mabs Therapeutics Inc 's Quick Ratio to 2.84, Quick Ratio remained below YMAB average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 450 other companies have achieved higher Quick Ratio than Y Mabs Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2025 from 2355 to 3433.

Explain Quick Ratio?
How much Cash & cash equivalents YMAB´s has?
What are YMAB´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 451
Healthcare Sector # 919
Within the Market # 3433


trailing twelve months Quick Ratio Statistics
High Average Low
14.62 7.1 2.45
(Mar 31 2019)   (Mar 31 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2025 MRQ Cash & cash equivalentJun 30 2025 MRQ Current Liabilities
Sensei Biotherapeutics Inc   7.39 $ 28.628  Millions$ 3.873  Millions
Zentalis Pharmaceuticals Inc   7.35 $ 286.640  Millions$ 39.022  Millions
Mirum Pharmaceuticals Inc   7.32 $ 325.898  Millions$ 44.495  Millions
Dogwood Therapeutics inc   7.32 $ 13.403  Millions$ 1.831  Millions
Adicet Bio Inc   7.32 $ 124.963  Millions$ 17.079  Millions
Generation Bio Co   7.30 $ 141.363  Millions$ 19.370  Millions
Compass Pathways Plc  7.22 $ 222.260  Millions$ 30.773  Millions
Actinium Pharmaceuticals Inc  7.21 $ 59.928  Millions$ 8.314  Millions
Zevra Therapeutics Inc   7.03 $ 202.611  Millions$ 28.832  Millions
Kezar Life Sciences Inc   7.02 $ 100.849  Millions$ 14.365  Millions
Silence Therapeutics Plc  6.96 $ 141.108  Millions$ 20.265  Millions
Uniqure N v   6.86 $ 253.778  Millions$ 37.020  Millions
Vyne Therapeutics Inc   6.82 $ 39.647  Millions$ 5.811  Millions
Matinas Biopharma Holdings Inc   6.78 $ 6.525  Millions$ 0.962  Millions
Barinthus Biotherapeutics Plc  6.78 $ 86.259  Millions$ 12.725  Millions
Amarin Corp Plcuk  6.69 $ 299.004  Millions$ 44.711  Millions
Coya Therapeutics Inc   6.61 $ 29.757  Millions$ 4.501  Millions
Neuphoria Therapeutics Inc   6.59 $ 9.441  Millions$ 1.433  Millions
Tonix Pharmaceuticals Holding Corp   6.58 $ 125.331  Millions$ 19.061  Millions
Bolt Biotherapeutics Inc   6.56 $ 50.265  Millions$ 7.659  Millions
Abeona Therapeutics Inc   6.53 $ 225.518  Millions$ 34.517  Millions
Kiora Pharmaceuticals Inc   6.49 $ 20.666  Millions$ 3.186  Millions
Silo Pharma Inc  6.40 $ 6.260  Millions$ 0.978  Millions
Calcimedica Inc   6.40 $ 17.957  Millions$ 2.807  Millions
Spyre Therapeutics Inc   6.34 $ 526.580  Millions$ 83.059  Millions
Dermata Therapeutics Inc   6.32 $ 6.481  Millions$ 1.026  Millions
Praxis Precision Medicines Inc   6.30 $ 301.275  Millions$ 47.853  Millions
Rocket Pharmaceuticals Inc   6.26 $ 271.494  Millions$ 43.399  Millions
Theravance Biopharma inc   6.20 $ 338.804  Millions$ 54.633  Millions
Minerva Neurosciences Inc   6.03 $ 15.248  Millions$ 2.529  Millions

Date modified: 2026-08-29T17:41:26+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.